Oncotarget

Exploring the role of cancer-associated fibroblasts in colon cancer progression, specifically focusing on IL-6 secretion and the influence of retinol metabolism in CAFs. Researchers discuss new insights and potential treatment strategies in addressing tumor-promoting inflammation.

Dr. Georg F. Weber from the University of Cincinnati discusses women's health and the difficult decision-making process around treating non-cancerous lumps in the breast. They explore options like surgery, radiation, and hormone therapy, emphasizing the need for biomarkers to guide effective management.

Discover the crucial role of EGFR in cancer and how dysregulation affects therapy. Explore the impact of endocytosis on signaling pathways and drug resistance. Uncover the complexities of SNX3 in breast cancer and its influence on EGFR pathways and tumor characteristics.

Researchers delve into the roles of STAT3 isoforms in aggressive breast cancer, highlighting the opposing functions of STAT3α and STAT3β, shedding light on the complex behavior of cancer cells.

Researchers Zhaoshan Liu, Swati Choksi, and Zheng-Gang Liu discuss how tumor necroptosis promotes metastasis by modulating tumor-host immunity. They explore the role of different forms of cell death in tumorigenesis, highlighting necroptosis as a promoting factor in tumor progression. The podcast also delves into the potential implications of inhibiting necroptosis to reduce cancer metastasis.

Researchers conducted a study on CA 19-9 and CEA as prognostic markers in duodenal adenocarcinoma, revealing the potential value of elevated levels in predicting patient outcomes and mortality from 2006-2021.

The podcast delves into the genetic theory of cancer evolution, focusing on how therapy impacts metastatic cancer's genomic evolution and resistance. They explore mechanisms of metastatic cancer, gatekeeper genomic events, and discuss a recent study on therapy resistance in tumors. Understanding genetic mutations and tumor origins is key to advancing cancer treatments.

Researcher Mikhail V. Blagosklonny discusses how rapamycin and other rapalogs can delay cancer by targeting pre-cancerous cells and slowing organismal aging. Clinical trials in high-risk populations are warranted to explore their cancer-preventive effects.

New research paper published in Oncotarget discusses phase I trial of riluzole and sorafenib in patients with advanced solid tumors, showing promising antitumor activity. Researchers identified toxicity profile, dose-limiting toxicities, maximum tolerated dose, and pharmacokinetic properties of the combination. Exploration of overexpression of GRM1 in cancer pathogenesis and efficacy of the combination therapy in patients with refractory solid tumors.

Explore the challenges in treating Triple Negative Breast Cancer (TNBC) despite advancements. Emphasize the importance of molecular markers in treatment regimens. Discuss potential therapeutic strategies to enhance TNBC outcomes.